Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Guardant Health, Inc.GH · Entity 3238 | Director · Co-Chief Executive Officer | September 30, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Guardant Health, Inc.
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectShares held by Talasaz and Eskandari 2017 Family Trust | 1,827,168 |
Reported balance
After 2026-09-30 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-09-30 · Exercise / conversion · Acquired 2,817 · Balance 1,827,168 |
| Common StockSEC Table I · non-derivative | IndirectShares held by Talasaz and Eskandari 2017 Family Trust | 1,825,740 |
Reported balance
After 2026-09-30 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-09-30 · Tax withholding · Disposed 1,428 · Balance 1,825,740 F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. |
| Common StockSEC Table I · non-derivative | IndirectShares held by Talasaz and Eskandari 2017 Family Trust | 1,849,737 |
Reported balance
After 2026-10-01 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-10-01 · Exercise / conversion · Acquired 23,997 · Balance 1,849,737 |
| Common StockSEC Table I · non-derivative | IndirectShares held by Talasaz and Eskandari 2017 Family Trust | 1,859,453 |
Reported balance
After 2026-10-01 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2026-10-01 · Exercise / conversion · Acquired 9,716 · Balance 1,859,453 |
| Common StockSEC Table I · non-derivative | IndirectShares held by Talasaz and Eskandari 2017 Family Trust | 1,842,366 |
Reported balance
After 2026-10-01 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2026-10-01 · Tax withholding · Disposed 17,087 · Balance 1,842,366 F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 2,817 |
Reported balance
After 2026-09-30 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-30 · Exercise / conversion · Disposed 2,817 · Balance 2,817 F2: This represents a restricted stock unit award granted on March 17, 2026 that vests in four equal installments on the last day of each calendar quarter, March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026. F3: Not applicable for Restricted Stock Units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 23,998 |
Reported balance
After 2026-10-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-10-01 · Exercise / conversion · Disposed 23,997 · Balance 23,998 F4: This represents a restricted stock unit award granted on March 18, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3: Not applicable for Restricted Stock Units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 48,580 |
Reported balance
After 2026-10-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-10-01 · Exercise / conversion · Disposed 9,716 · Balance 48,580 F5: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3: Not applicable for Restricted Stock Units. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.
F2: This represents a restricted stock unit award granted on March 17, 2026 that vests in four equal installments on the last day of each calendar quarter, March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026.
F3: Not applicable for Restricted Stock Units.
F4: This represents a restricted stock unit award granted on March 18, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
F5: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 3, 2026 00:58 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 9,716 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001753159-26-000022 · wk-form4_1790974735.xml · derivative · entry 8 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,580 Underlying: Common Stock · 9,716 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| October 01, 2026 Filed Oct 3, 2026 00:58 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 23,997 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001753159-26-000022 · wk-form4_1790974735.xml · derivative · entry 7 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,998 Underlying: Common Stock · 23,997 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This represents a restricted stock unit award granted on March 18, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| October 01, 2026 Filed Oct 3, 2026 00:58 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCommon Stock | 17,087 | $174.75 | $2,985,953.25 |
DisclosureSEC source: 0001753159-26-000022 · wk-form4_1790974735.xml · nonDerivative · entry 5 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 1,842,366 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| October 01, 2026 Filed Oct 3, 2026 00:58 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 9,716 | $0.00 | $0.00 |
DisclosureSEC source: 0001753159-26-000022 · wk-form4_1790974735.xml · nonDerivative · entry 4 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 1,859,453 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2026 Filed Oct 3, 2026 00:58 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 23,997 | $0.00 | $0.00 |
DisclosureSEC source: 0001753159-26-000022 · wk-form4_1790974735.xml · nonDerivative · entry 3 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 1,849,737 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2026 Filed Oct 3, 2026 00:58 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 2,817 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001753159-26-000022 · wk-form4_1790974735.xml · derivative · entry 6 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,817 Underlying: Common Stock · 2,817 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This represents a restricted stock unit award granted on March 17, 2026 that vests in four equal installments on the last day of each calendar quarter, March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| September 30, 2026 Filed Oct 3, 2026 00:58 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCommon Stock | 1,428 | $178.36 | $254,698.08 |
DisclosureSEC source: 0001753159-26-000022 · wk-form4_1790974735.xml · nonDerivative · entry 2 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 1,825,740 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| September 30, 2026 Filed Oct 3, 2026 00:58 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 2,817 | $0.00 | $0.00 |
DisclosureSEC source: 0001753159-26-000022 · wk-form4_1790974735.xml · nonDerivative · entry 1 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 1,827,168 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 21, 2026 Filed Aug 24, 2026 21:21 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 7,589 | $170.29 | $1,292,301.97 |
DisclosureSEC source: 0001753159-26-000020 · wk-form4_1787606490.xml · nonDerivative · entry 3 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Shares held by the Talasaz Family Foundation Disclosed balance after: 37,500 F3 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $169.88 to $170.50. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 21, 2026 Filed Aug 24, 2026 21:21 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 20,888 | $169.16 | $3,533,451.68 |
DisclosureSEC source: 0001753159-26-000020 · wk-form4_1787606490.xml · nonDerivative · entry 2 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Shares held by the Talasaz Family Foundation Disclosed balance after: 45,089 F2 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $168.87 to $169.73. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 21, 2026 Filed Aug 24, 2026 21:21 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 9,023 | $168.20 | $1,517,630.70 |
DisclosureSEC source: 0001753159-26-000020 · wk-form4_1787606490.xml · nonDerivative · entry 1 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Shares held by the Talasaz Family Foundation Disclosed balance after: 65,977 F1 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $167.81 to $168.60. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 22:20 UTC | Guardant Health, Inc. GH · Entity 3238 | GiftCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001753159-26-000018 · wk-form4_1786573235.xml · nonDerivative · entry 2 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Shares held by the Talasaz Family Foundation Disclosed balance after: 75,000 F1 · shares: Reflects changes in form of ownership from Talasaz and Eskandari 2017 Family Trust due to the gift of shares to The Talasaz Family Foundation. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 22:20 UTC | Guardant Health, Inc. GH · Entity 3238 | GiftCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001753159-26-000018 · wk-form4_1786573235.xml · nonDerivative · entry 1 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 1,824,351 F1 · shares: Reflects changes in form of ownership from Talasaz and Eskandari 2017 Family Trust due to the gift of shares to The Talasaz Family Foundation. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 22:09 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 9,715 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001753159-26-000016 · wk-form4_1783030139.xml · derivative · entry 8 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,296 Underlying: Common Stock · 9,715 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 22:09 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 23,997 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001753159-26-000016 · wk-form4_1783030139.xml · derivative · entry 7 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,995 Underlying: Common Stock · 23,997 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This represents a restricted stock unit award granted on March 18, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 22:09 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCommon Stock | 17,086 | $170.77 | $2,917,776.22 |
DisclosureSEC source: 0001753159-26-000016 · wk-form4_1783030139.xml · nonDerivative · entry 5 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 1,899,351 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 22:09 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 9,715 | $0.00 | $0.00 |
DisclosureSEC source: 0001753159-26-000016 · wk-form4_1783030139.xml · nonDerivative · entry 4 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 1,916,437 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 22:09 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 23,997 | $0.00 | $0.00 |
DisclosureSEC source: 0001753159-26-000016 · wk-form4_1783030139.xml · nonDerivative · entry 3 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 1,906,722 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 22:09 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 2,817 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001753159-26-000016 · wk-form4_1783030139.xml · derivative · entry 6 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,634 Underlying: Common Stock · 2,817 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This represents a restricted stock unit award granted on March 17, 2026 that vests in four equal installments on the last day of each calendar quarter, March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 22:09 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCommon Stock | 1,428 | $150.03 | $214,242.84 |
DisclosureSEC source: 0001753159-26-000016 · wk-form4_1783030139.xml · nonDerivative · entry 2 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 1,882,725 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 22:09 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 2,817 | $0.00 | $0.00 |
DisclosureSEC source: 0001753159-26-000016 · wk-form4_1783030139.xml · nonDerivative · entry 1 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 1,884,153 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2026 Filed Jun 30, 2026 21:13 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionStock Option (Right to Buy) · Derivative | 143,028 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001753159-26-000014 · wk-form4_1782854022.xml · derivative · entry 10 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,997 Underlying: Common Stock · 143,028 shares Expires 2027-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vested in equal monthly installments over 48 months commencing on April 23, 2017. Read SEC document |
| June 29, 2026 Filed Jun 30, 2026 21:13 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 40 | $153.00 | $6,120.00 |
DisclosureSEC source: 0001753159-26-000014 · wk-form4_1782854022.xml · nonDerivative · entry 8 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 1,881,336 Read SEC document |
| June 29, 2026 Filed Jun 30, 2026 21:13 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 46,663 | $152.20 | $7,102,318.58 |
DisclosureSEC source: 0001753159-26-000014 · wk-form4_1782854022.xml · nonDerivative · entry 7 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 1,881,376 F4 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $152.00 to $152.68. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 29, 2026 Filed Jun 30, 2026 21:13 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 70,513 | $151.47 | $10,680,315.01 |
DisclosureSEC source: 0001753159-26-000014 · wk-form4_1782854022.xml · nonDerivative · entry 6 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 1,928,039 F3 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $151.00 to $151.99. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 29, 2026 Filed Jun 30, 2026 21:13 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 25,812 | $150.53 | $3,885,433.90 |
DisclosureSEC source: 0001753159-26-000014 · wk-form4_1782854022.xml · nonDerivative · entry 5 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 1,998,552 F1 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $150.00 to $150.99. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 29, 2026 Filed Jun 30, 2026 21:13 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 143,028 | $4.18 | $597,857.04 |
DisclosureSEC source: 0001753159-26-000014 · wk-form4_1782854022.xml · nonDerivative · entry 4 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 2,024,364 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 21:13 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionStock Option (Right to Buy) · Derivative | 111,804 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001753159-26-000014 · wk-form4_1782854022.xml · derivative · entry 9 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 172,025 Underlying: Common Stock · 111,804 shares Expires 2027-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vested in equal monthly installments over 48 months commencing on April 23, 2017. Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 21:13 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 52,935 | $151.16 | $8,001,628.13 |
DisclosureSEC source: 0001753159-26-000014 · wk-form4_1782854022.xml · nonDerivative · entry 3 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 1,881,336 F2 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $151.00 to $151.79. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 21:13 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 64,037 | $150.49 | $9,636,838.48 |
DisclosureSEC source: 0001753159-26-000014 · wk-form4_1782854022.xml · nonDerivative · entry 2 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 1,934,271 F1 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $150.00 to $150.99. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 21:13 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 111,804 | $4.18 | $467,340.72 |
DisclosureSEC source: 0001753159-26-000014 · wk-form4_1782854022.xml · nonDerivative · entry 1 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 1,998,308 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:57 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 26,352 | $112.76 | $2,971,430.44 |
DisclosureSEC source: 0001753159-26-000012 · wk-form4_1779483475.xml · nonDerivative · entry 12 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 1,886,504 F11 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $112.74 to $112.93. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:57 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 37,900 | $112.02 | $4,245,546.63 |
DisclosureSEC source: 0001753159-26-000012 · wk-form4_1779483475.xml · nonDerivative · entry 11 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 1,912,856 F10 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $111.73 to $112.70. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:57 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 37,163 | $111.14 | $4,130,470.49 |
DisclosureSEC source: 0001753159-26-000012 · wk-form4_1779483475.xml · nonDerivative · entry 10 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 1,950,756 F9 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $110.72 to $111.71. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:57 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 28,908 | $110.10 | $3,182,652.28 |
DisclosureSEC source: 0001753159-26-000012 · wk-form4_1779483475.xml · nonDerivative · entry 9 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 1,987,919 F8 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $109.66 to $110.58. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:57 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 9,852 | $108.97 | $1,073,546.82 |
DisclosureSEC source: 0001753159-26-000012 · wk-form4_1779483475.xml · nonDerivative · entry 8 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 2,016,827 F7 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $108.59 to $109.56. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:57 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 33,069 | $108.11 | $3,574,960.62 |
DisclosureSEC source: 0001753159-26-000012 · wk-form4_1779483475.xml · nonDerivative · entry 7 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 2,026,679 F6 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $107.59 to $108.57. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:57 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 21,171 | $106.99 | $2,265,125.51 |
DisclosureSEC source: 0001753159-26-000012 · wk-form4_1779483475.xml · nonDerivative · entry 6 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 2,059,748 F5 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $106.57 to $107.52. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:57 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 1,200 | $105.88 | $127,050.00 |
DisclosureSEC source: 0001753159-26-000012 · wk-form4_1779483475.xml · nonDerivative · entry 5 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 2,080,919 F4 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $105.49 to $106.42. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:57 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 11,919 | $105.01 | $1,251,589.16 |
DisclosureSEC source: 0001753159-26-000012 · wk-form4_1779483475.xml · nonDerivative · entry 4 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 2,082,119 F3 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $104.400 to $105.39. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:57 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 1,366 | $103.82 | $141,815.11 |
DisclosureSEC source: 0001753159-26-000012 · wk-form4_1779483475.xml · nonDerivative · entry 3 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 2,094,038 F2 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $103.40 to $104.26. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:57 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 900 | $102.57 | $92,313.00 |
DisclosureSEC source: 0001753159-26-000012 · wk-form4_1779483475.xml · nonDerivative · entry 2 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 2,095,404 F1 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $102.29 to $103.06. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:57 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 200 | $100.95 | $20,190.00 |
DisclosureSEC source: 0001753159-26-000012 · wk-form4_1779483475.xml · nonDerivative · entry 1 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 2,096,304 Read SEC document |
| May 12, 2026 Filed May 13, 2026 21:32 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 50,000 | $100.32 | $5,016,000.00 |
DisclosureSEC source: 0001753159-26-000010 · wk-form4_1778707917.xml · nonDerivative · entry 1 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 2,096,504 F1 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.30 to $100.34. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 21:19 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 9,716 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001753159-26-000008 · wk-form4_1775164793.xml · derivative · entry 8 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,011 Underlying: Common Stock · 9,716 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 21:19 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 23,997 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001753159-26-000008 · wk-form4_1775164793.xml · derivative · entry 7 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,992 Underlying: Common Stock · 23,997 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This represents a restricted stock unit award granted on March 18, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 21:19 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCommon Stock | 17,087 | $91.15 | $1,557,480.05 |
DisclosureSEC source: 0001753159-26-000008 · wk-form4_1775164793.xml · nonDerivative · entry 5 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 2,146,504 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 21:19 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 9,716 | $0.00 | $0.00 |
DisclosureSEC source: 0001753159-26-000008 · wk-form4_1775164793.xml · nonDerivative · entry 4 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 2,163,591 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 21:19 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 23,997 | $0.00 | $0.00 |
DisclosureSEC source: 0001753159-26-000008 · wk-form4_1775164793.xml · nonDerivative · entry 3 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 2,153,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 21:19 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 2,817 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001753159-26-000008 · wk-form4_1775164793.xml · derivative · entry 6 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,451 Underlying: Common Stock · 2,817 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This represents a restricted stock unit award granted on March 17, 2026 that vests in four equal installments on the last day of each calendar quarter: March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.